Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
The phase II, multicenter study looked at the combination of melflufen and Dexamethasone (Ozurdex) in patients with relapsed/refractory multiple myeloma who were refractory to pomalidomide (Pomalyst), daratumumab (Darzalex), or both.
The safety profiles showed that most toxicities were grades 1 and 2. Expected adverse events like suppression of blood counts, hair loss, mucositis, and peripheral neuropathy were either manageable or did not occur.
IKEMA Shows Advantage for Anti-CD38 in 1q21+ R/R Multiple Myeloma
March 22nd 2024During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series
Read More
Phase 2 and 3 Transplant-Eligible NDMM Data Build Evidence for Quadruplet Therapy
March 20th 2024During a Case-Based Roundtable® event, Laahn Foster, MD, discussed the GRIFFIN, MASTER, and PERSEUS trials in transplant-eligible newly diagnosed multiple myeloma in the first article of a 2-part series.
Read More
Ixabepilone/Bevacizumab Improves PFS and OS in Platinum-Resistant/Refractory Ovarian Cancer
March 19th 2024Combining ixabepilone with bevacizumab generated improved survival rates and high response rates compared with ixabepilone monotherapy in platinum-resistant or platinum-refractory ovarian cancer.
Read More